AGT and Alzheimer disease: On the other hand, rapamycin showed a striking suppression of AD development after 14-day BAPN + AngII challenge (Figure 1B, Table 1, p < 0.01 by Fisher’s exact test) without significant changes in systolic blood pressure, pulse rate or body weight (Figure S1).